Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk

Beuselinck, Benoît; Verbiest, Annelies; Couchy, Gabrielle; Job, Sylvie; Reyniès, Aurélien de; Caruso, Stefano; Verkarre, Virginie; Rioux‐Leclercq, Nathalie; Schöffski, Patrick; Vano, Yann; Elaidi, R.T.; Lerut, Evelyne; Albersen, Maarten; Оудард, С.; Zucman–Rossi, Jessica

doi:10.1093/annonc/mdy283.078

Cited by 9 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of IMDC favorable-risk patients had the ccrcc2 molecular subtype, characterized by high expression of pro-angiogenic genes. It is hypothesized that this may account for the enhanced responses to sunitinib in patients with favorable risk compared with nivolumab plus ipilimumab observed in the Checkmate 214 trial (NCT02231749) [55]. The integration of genomic markers into updated prognostic models may not only improve patient stratification, but also help guide patient management, including the optimal sequence of treatment for patients who progress on their current treatment.…”

Section: Future Perspectivementioning

confidence: 99%

The Clinical Significance of Routine Risk Categorization in Metastatic Renal Cell Carcinoma and its Impact on Treatment Decision-Making: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Aim: To analyze responses to first-line metastatic renal cell carcinoma (mRCC) treatment stratified by risk criteria. Patients & methods: Clinical trials and observational studies of patients aged ≥18 years, published January 2005–May 2019, were identified via Ovid from MEDLINE, EMBASE, the Cochrane Central Trials Register and the Cochrane Database of Systematic Reviews. Data extracted included progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). Results: 47/1269 articles met eligibility criteria. Most studies stratified patients by International Metastatic RCC Database Consortium (n = 19) or Memorial Sloan Kettering Cancer Center (n = 21). PFS, OS and ORR varied according to risk group. Conclusion: Pembrolizumab + axitinib, ipilimumab + nivolumab and avelumab + axitinib were most effective across all risk groups. Favorable-risk patients benefit from sunitinib treatment.

show abstract

Section: Future Perspectivementioning

confidence: 99%

The Clinical Significance of Routine Risk Categorization in Metastatic Renal Cell Carcinoma and its Impact on Treatment Decision-Making: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A global transcriptome analyses of tumors from patients with clear cell mRCC who received first-line sunitinib identified of 4 molecular subtypes (ccrcc1-4) [44]. Patients with the ccrcc2 molecular subtype, which is characterized by a high expression of pro-angiogenic genes, were mostly of IMDC favorable risk [45,46]. These observations may explain the improved ORR and PFS in sunitinib-treated patients with favorable risk compared with those who received nivolumab plus ipilimumab in the CheckMate 214 trial.…”

Section: Discussionmentioning

confidence: 97%

Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma According to Risk Factors: The STAR-TOR Registry

et al. 2021

View full text Add to dashboard Cite

Aim: Examine outcomes in sunitinib-treated patients by International Metastatic RCC Database Consortium (IMDC) or Memorial Sloan-Kettering Cancer Center (MSKCC) risk factors. Patients & methods: Patients enrolled in STAR-TOR registry (n = 327). End points included overall survival, progression-free survival and objective response rate. Results: Overall survival was similar for IMDC 0 versus 1 (p = 0.238) or 2 versus ≥3 (p = 0.156), but different for MSKCC (0 vs 1, p = 0.037; 2 vs ≥3, p = 0.001). Progression-free survival was similar for IMDC 2 versus 3 (p = 0.306), but different for MSKCC (p = 0.009). Objective response rate was different for IMDC 1 (41.9%) and 2 (29.5%) and similar for MSKCC 1 (34.4%) and 2 (31.0%). Conclusion: Outcome data varied according to IMDC or MSKCC. MSKCC model accurately stratify patients into risk groups. Clinical trial registration: NCT00700258 (ClinicalTrials.gov)

show abstract

“…These molecular profiles may be supportive to predict response, PFS and OS in patients treated with TKIs [11]. This actually may explain the increased benefit of sunitinib versus ipilimumab-nivolumab in good risk patients in CheckMate214 [53]. Therefore, with combined ipilimumab-nivolumab, some patients may be overtreated.…”

Section: Discussionmentioning

confidence: 98%

A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus

et al. 2020

View full text Add to dashboard Cite

BackgroundThis article describes and compares approved targeted therapies and the newer immunotherapy agents. Materials and methodsThis article especially performs an in-depth review of currently available data for tivozanib, explaining its mechanism of action, its safety profle and its role as an efcacy drug in the management of renal cancer. ResultsDespite the fact that the treatment of advanced RCC has been dramatically modifed in recent years, durable remissions are scarce and it remains a lethal disease. For frst-and second-line therapy, there is now growing evidence to guide the selection of the appropriate treatment. ConclusionsSeveral TKIs are standard of care at diferent settings. Among those approved TKIs, tivozanib has similar efcacy than others with a better safety profle. The use of prognostic factors is critical to the selection of optimal therapy.

show abstract

Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk

Cited by 9 publications

References 0 publications

The Clinical Significance of Routine Risk Categorization in Metastatic Renal Cell Carcinoma and its Impact on Treatment Decision-Making: A Systematic Review

The Clinical Significance of Routine Risk Categorization in Metastatic Renal Cell Carcinoma and its Impact on Treatment Decision-Making: A Systematic Review

Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma According to Risk Factors: The STAR-TOR Registry

A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus

Contact Info

Product

Resources

About